Introduction
Methods
Study design and patients
Objective
Data collection
Analyses of self-reported QoL
Statistical analysis
Results
Patient’s characteristics
Total n = 112 (100%) | Reference n = 27 (24%) | VA n = 29 (26%) | Rad n = 32 (29%) | RadVA n = 24 (21%) | |
---|---|---|---|---|---|
Sex | |||||
Men, n (%) | 50 (45) | 15 (56) | 6 (21) | 17 (53) | 12 (50) |
Women, n (%) | 62 (55) | 12 (44) | 23 (79) | 15 (47) | 12 (50) |
p = 0.016* | p = 1 | p = 0.908 | |||
Age, years | |||||
Median (IQR) | 70 (63–75) | 71 (64–76) | 65 (58–74) | 72 (67–76) | 68 (62–75) |
p = 0.119 | p = 0.659 | p = 0.363 | |||
Histology | |||||
Non-small cell LC (NSCLC) | 103 (92) | 25 (93) | 29 (100) | 31 (97) | 18 (75) |
Small cell LC (SCLC) | 6 (5) | 0 | 0 | 1 (3) | 5 (21) |
Other# | 3 (3) | 2 (7) | 0 | 0 | 1 (4) |
p = 0.328 | p = 0.198 | p = 0.042* | |||
UICC tumor stage | |||||
I | 23 (21) | 11 (41) | 2 (7) | 10 (31) | 0 |
II | 13 (12) | 6 (22) | 2 (7) | 5 (16) | 0 |
III | 30 (27) | 6 (22) | 6 (21) | 10 (31) | 8 (33) |
IV | 46 (41) | 4 (15) | 19 (66) | 7 (22) | 6 (67) |
p = 0.0004* | p = 0.672 | p = 0.0018* |
Treatments n = 112 (100%) | N (%) |
---|---|
Surgery, n (%) 62 (55) | 62 (100) |
Elective | 60 (97) |
Revision | 3 (5) |
Emergency | 2 (3) |
Radiation (Rad), n (%) 56 (50) | 56 (100) |
Thorax | 45 (80) |
Brain | 14 (25) |
Skeleton | 7 (13) |
Chemotherapy, n (%) 69 (62) | 69 (100) |
Platinum compounds | 58 (84) |
Vinorelbine | 32 (46) |
Pemetrexed | 18 (26) |
Taxanes | 16 (23) |
Etoposide | 9 (13) |
Gemicitabine | 2 (3) |
Bisphosphonates | 11 (16) |
Targeted, n (%) 47 (42) | 47 (100) |
Kinase inhibitors | 15 (32) |
Immune checkpoint inhibitors | 33 (70) |
Viscum album L. (VA), n (%) 53 (47) | 53 (100) |
Subcutaneous | 49 (92) |
Intravenous | 35 (66) |
Intra-tumoural/-pleural | 3 (6) |
Evaluation of longitudinal EORTC QLQ-C30 changes
EORTC QLQ-C30 | Key | T0 | T1 | T0–> T1 | ||||
---|---|---|---|---|---|---|---|---|
n = 112 | Mean | SD | Mean | SD | Changes | IQR | p-values | |
Global health status/QoL | QL | 47.92 | 21.40 | 54.28 | 24.43 | 6.46 | − 8.3 to 16.7 | 0.006* |
Physical functioning | PF | 62.70 | 24.79 | 58.15 | 24.95 | − 4.56 | − 20.0 to 13.3 | 0.063 |
Role functioning | RF | 54.35 | 34.57 | 52.23 | 34.47 | − 2.25 | − 16.7 to 16.7 | 0.531 |
Emotional functioning | EF | 50.61 | 22.55 | 58.04 | 28.30 | 7.58 | − 8.3 to 25.0 | 0.006* |
Cognitive functioning | CF | 59.70 | 27.00 | 57.59 | 28.25 | − 1.82 | − 16.7 to 16.7 | 0.495 |
Social functioning | SF | 60.49 | 30.81 | 57.89 | 32.27 | − 3.40 | − 16.7 to 16.7 | 0.269 |
Fatigue | FA | 52.83 | 27.39 | 53.87 | 26.15 | 0.91 | − 11.1 to 11.1 | 0.737 |
Nausea and vomiting | NV | 10.06 | 19.41 | 10.42 | 20.79 | 0.45 | 0–0 | 0.845 |
Pain | PA | 37.74 | 35.56 | 38.39 | 33.98 | 0.63 | − 16.7 to 33.3 | 0.860 |
Dyspnea | DY | 52.73 | 37.97 | 54.65 | 36.57 | 1.53 | − 33.3 to 33.3 | 0.680 |
Insomnia | SL | 47.04 | 36.73 | 42.26 | 37.79 | − 5.61 | − 33.3 to 33.3 | 0.171 |
Appetite loss | AP | 38.84 | 35.12 | 30.36 | 37.68 | − 9.17 | − 33.3 to 0 | 0.015* |
Constipation | CO | 26.67 | 37.01 | 21.32 | 32.51 | − 5.20 | − 33.3 to 0 | 0.159 |
Diarrhea | DI | 13.03 | 26.63 | 15.32 | 25.23 | 2.45 | 0–0 | 0.426 |
Financial difficulties | FI | 20.32 | 29.28 | 27.38 | 30.61 | 6.98 | 0–33.3 | 0.01* |